Myelodysplastic Syndromes (MDS)

Transplant for MDS, or Myelodysplastic Syndromes, from the Patient and Family Conference, Utah, 2023

Topic(s)

Presenter(s)

Ryotaro Nakamura, MD

Ryotaro Nakamura, MD, City Of Hope, explains the reasons why the specialist may recommend a bone marrow transplant for a patient with MDS. The recording includes questions from the audience.

Ask the Pediatric Experts: Session from the Patient and Family Conference in Salt Lake City, UT 2023

Thumbnail for video Watch Now

Topic(s)

Related Bone Marrow Failure Diseases and Malignancies

Pediatric Bone Marrow Failure Diseases

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Bone Marrow Transplant

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Presenter(s)

Suneet Agarwal, MD, PhD

Michael Pulsipher, MD

Suneet Agarwal, MD, PhD, from Boston Children's Hospital answered parents' questions in this session from the Patient and Family Conference in Salt Lake City, Utah. Find the answers to your most pressing question in this recording.

MDS and Non-Transplant Therapies from the Patient and Family Conference in Salt Lake City, UT, 2023

Thumbnail for video Watch Now

Topic(s)

Myelodysplastic Syndromes (MDS)

Presenter(s)

PAUL J. SHAMI, MD

Paul J Shami, MD of Huntsman Cancer Institute describes the types of therapies that may be used in treating MDS, or Myelodysplastic Syndromes that do not include a bone marrow transplant.

PAUL J. SHAMI, MD

Institution

Huntsman Cancer Institute

Physician Status

accepting new patients

Primary Disease Area of Focus

Myelodysplastic Syndromes (MDS)

About

Languages Spoken: English, French, Arabic Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and is a Member and Clinical Investigator at the University’s Huntsman Cancer Institute (HCI). Dr. Shami also holds an Adjunct appointment as a Professor of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. He is Board Certified in Hematology and Medical Oncology. He started at the University of Utah in 1997. Dr. Shami oversees leukemia clinical trials at Huntsman Cancer Institute. His research also includes

Read more about PAUL J. SHAMI, MD

Predisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023

Thumbnail for video Watch Now

Topic(s)

Pediatric Bone Marrow Failure Diseases

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Presenter(s)

Suneet Agarwal, MD, PhD

Suneet Agarwal, MD, PhD from Boston's Children's Hospital provides essential information for families about inherited bone marrow failure disorders in this session from the Patient and Family Conference in Salt Lake City, UT, 2023

Prajwal Dhakal, MD

Institution

University of Iowa Health Care

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Read more about Prajwal Dhakal, MD

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Read more about Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Background: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Read more about Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Purpose: In myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Read more about Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders

Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

Read more about Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

Subscribe to Myelodysplastic Syndromes (MDS)

Your Gift Today Changes Lives

Myelodysplastic Syndromes (MDS)

Transplant for MDS, or Myelodysplastic Syndromes, from the Patient and Family Conference, Utah, 2023

Ask the Pediatric Experts: Session from the Patient and Family Conference in Salt Lake City, UT 2023

MDS and Non-Transplant Therapies from the Patient and Family Conference in Salt Lake City, UT, 2023

PAUL J. SHAMI, MD

Predisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023

Prajwal Dhakal, MD

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study

Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

Website Feedback

Patient Helpline